Four cases of natalizumab-related PML: a less severe course in extended interval dosing?

Cristina ScarpazzaNicola De RossiGiulietta TabiadonMaria Vittoria TurriniSimonetta GereviniRuggero Capra

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2019)

Although PML in EID seems to occur less frequently than in conventional dosing regimen, strict monitoring of high-risk patients contributed to the indolent course observed in the four described cases, characterized by a prolonged pre-symptomatic phase, paucisymptomatic onset, low JCv load, less severe functional impairment during immune reconstitution, and a mild disability burden.

Keyphrases

multiple sclerosis
end stage renal disease
newly diagnosed
chronic kidney disease
early onset
prognostic factors
peritoneal dialysis
drug induced
risk factors
patient reported outcomes